Feasibility of clinical studies of chemical exchange saturation transfer magnetic resonance imaging of prostate cancer at 7 T.
Daan J ReesinkCatalina Arteaga de CastroTijl Antonius van der VeldenJeanette Van VoorenPetri OostTrudy G N JongesMarnix G E H LamBart de KeizerPeter-Paul M WillemseRichard P MeijerDennis W J KlompPublished in: NMR in biomedicine (2023)
Chemical exchange saturation transfer (CEST) has been explored for differentiation between tumour and benign tissue in prostate cancer (PCa) patients. With ultrahigh field strengths such as 7-T, the increase of spectral resolution and sensitivity could allow for selective detection of amide proton transfer (APT) at 3.5 ppm and a group of compounds that resonate at 2 ppm (i.e., [poly]amines and/or creatine). The potential of 7-T multipool CEST analysis of the prostate and the detection of PCa was studied in patients with proven localised PCa who were scheduled to undergo robot-assisted radical prostatectomy (RARP). Twelve patients were prospectively included (mean age 68.0 years, mean serum prostate-specific antigen 7.8ng/mL). A total of 24 lesions larger than 2 mm were analysed. Used were 7-T T2-weighted (T2W) imaging and 48 spectral CEST points. Patients received 1.5-T/3-T prostate magnetic resonance imaging and galium-68-prostate-specific membrane antigen-positron emission tomography/computerised tomography to determine the location of the single-slice CEST. Based on the histopathological results after RARP, three regions of interest were drawn on the T2W images from a known malignant zone and benign zone in the central and peripheral zones. These areas were transposed to the CEST data, from which the APT and 2-ppm CEST were calculated. The statistical significance of the CEST between the central zone, the peripheral zone, and tumour was calculated using a Kruskal-Wallis test. The z-spectra showed that APT and even a distinct pool that resonated at 2 ppm were detectable. This study showed a difference trend in the APT levels, but no difference in the 2-ppm levels when tested between the central zone, the peripheral zone, and tumour (H(2) = 4.8, p = 0.093 and H(2) = 0.86, p = 0.651, respectively). Thus, to conclude, we could most likely detect APT and amines and/or creatine levels noninvasively in prostate using the CEST effect. At group level, CEST showed a higher level of APT in the peripheral versus the central zone; however, no differences of APT and 2-ppm levels were observed in tumours.
Keyphrases
- prostate cancer
- radical prostatectomy
- magnetic resonance imaging
- robot assisted
- positron emission tomography
- end stage renal disease
- computed tomography
- ejection fraction
- newly diagnosed
- optical coherence tomography
- chronic kidney disease
- magnetic resonance
- high resolution
- prognostic factors
- benign prostatic hyperplasia
- peritoneal dialysis
- human health
- patient reported
- contrast enhanced
- patient reported outcomes
- risk assessment
- chemotherapy induced
- clinical decision support
- label free
- deep learning
- artificial intelligence
- fluorescence imaging
- big data
- molecular dynamics
- machine learning